Learn more about our pipeline and enrolling clinical trials
At argenx, our ethos is collaboration, where pioneering scientists and antibody engineers work side by side to accelerate the discovery of novel targets, disease pathways and differentiated medicines.
We are united in our dedication to patients, pursuing scientific breakthroughs for a better tomorrow.
Industry Therapeutic Update from argenx
From
discovery
to
practice: FcRn blockade and its role in CIDP and gMG
Visit medical booth #719
Our commitment to science and patients has no bounds
Monday, April 7; 6:00–8:00 pm Grand Ballroom, Marriott Marquis San Diego Marina Dinner will be served
Join us at 6:00 pm today to discover the latest clinical data on FcRn blockade in adult patients with CIDP and gMG. The session will feature patient case presentations and an interactive Q&A with expert neurologists.
AAN, American Academy of Neurology; CIDP, chronic inflammatory demyelinating polyneuropathy; FcRn, neonatal fragment crystallizable receptor; FDA, US Food and Drug Administration; gMG, generalized myasthenia gravis.
11:00 a.m.–5:30 p.m.
Poster Session 6
11:45 a.m.–12:45 p.m. Industry Therapeutic Updates 11:45 a.m.–12:45 p.m.
Poster Session 7
5:00 p.m.–6:00 p.m.
6:00 p.m.–8:00 p.m. Industry Therapeutic Updates
6:00 p.m.–8:00 p.m.
Start and end times may vary. Check with each hosting company for further information.
AAN Vision
To be indispensable to our members
AAN Mission
To enhance member career fulfillment and promote brain health for all
American Academy of Neurology 201 Chicago Avenue
Minneapolis, MN 55415 USA
Phone: (800) 879-1960 (Toll Free) or (612) 928-6000 (International)
Fax: (612) 454-2746
Email: memberservices@aan.com
Website: AAN.com
AAN Chief Executive Officer: Mary E. Post, MBA, CAE
Managing Editor: Angela M. Babb, MS, CAE, APR
Editor: Val Lick
Writers: Ryan Knoke, Sarah Parsons
Designer: Andrew Imholte
Photography: Will Evans
Annual Meeting Daily is published by the American Academy of Neurology. The American Academy of Neurology’s registered trademarks and service marks are registered in the United States and various other countries around the world.
CONTEMPORARY CLINICAL ISSUES
Experts to discuss critical practice issues in today’s Contemporary Clinical Issues Plenary
The issues most critical to practicing neurologists will be explored by leading researchers as they discuss abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments already affecting the practice of neurology during this morning’s Contemporary Clinical Issues Plenary. Set to take place between 9:15 a.m. and 11:00 a.m. in Ballroom 20, the session will be moderated by Fernando D. Testai, MD, PhD, FAAN.
Topics and presenters include:
Association Between NonEnglish Language Preference, Delirium Occurrence, and Inpatient Outcomes
Presenter: Mary C. Zuniga, MD, University of California San Francisco
Discussant: Nicole Gonzales, MD, University of Colorado
Impact of Rurality on Treatment and Survival in Patients with Brain Metastases
Presenter: Thomas Khodadad, University of Vermont
Discussant: Antonio M. P. Omuro, MD, FAAN, Stanford University
Autoimmune Encephalitis Is the Most Common TreatmentResponsive Cause of Rapidly Progressive Dementia: A Large Dutch Prospective Cohort Study
Presenter: Robin van Steenhoven, MD, Erasmus University Medical Center
Discussant: Stacey Clardy, MD, PhD, FAAN, University of Utah
Obstructive Sleep Apnea Is a Risk Factor for Parkinson’s Disease and CPAP Mitigates Risk of PD: An EHR-based Cohort Study in Military Veterans
Presenter: Isabella Montano, Oregon Health and Science University
Discussant: Roneil Malkani, MD, Northwestern University
Placental and Breastmilk Transfer of Ocrelizumab from Women with Multiple Sclerosis to Infants and the Potential Impact on B-Cell Levels: Primary Analysis of the Prospective, Multicenter, Open-label, Phase IV Studies MINORE and SOPRANINO
Presenter: Riley Bove, MD, FAAN, University of California, San Francisco
Discussant: Sandra Vukusic, MD, Lyon University Hospital
Continue the conversation at the follow-up popcorn talk!
11:00 a.m.-11:30 a.m.
Practice and Policy Hub (20D Lobby)
Practitioners are invited to continue the conversation from the Contemporary Clinical Issues Plenary Session. Join us as we break down the key points from the plenary and explain how physicians can use and/or relate to the content presented.
Exhibit Hall Networking Crawl offers food, connections, and fun!
Walk (don’t crawl!) to the Annual Meeting Exhibit Hall Networking Crawl starting at 4:00 p.m. for two hours of fun— and delicious—networking! Take a walking food tour to explore stations serving up a tasty array of cuisines and beverages while socializing with exhibitors and other attendees, including the always-popular Annual Meeting mascot Sarah Bellum™! This is an excellent and tasty opportunity to learn about the latest
advancements in patient care and products that add efficiencies to your practice while making lasting connections. Thanks to our Networking Crawl sponsors:
• C2N Diagnostics; Booth 907
• Grifols; Booth 2021
• Praxis Precision Medicines, Inc.; Booth 2113
Hint, hint: Puzzle out today’s crossword!
Take a break to follow these clues and solve today’s crossword puzzle, created by neuropsychologist Sarah Levy, PhD. Find her crosswords in each issue of Annual Meeting Daily! Solutions are on page 19.
Sarah Levy, PhD
Today’s Health Care Equity Symposium to highlight stroke equity
Join several experts today from 1:00 p.m. to 4:00 p.m. in 30AB for the annual Health Care Equity Symposium, which combines neurology with public health—a key to the AAN’s mission of promoting brain health for all. This event will begin with the keynote Cheryl A. Jay, MD, Lecture from Health Care Equity Research Award recipient Lesli E. Skolarus, MD, MS, who will discuss opportunities at the intersection of community and the medical system and explore the transformative potential of community engaged research in enhancing stroke preparedness and driving stroke prevention efforts. Attendees will have the chance to participate in a Q&A.
The symposium, which is directed by Nimish A. Mohile, MD, FAAN, will also feature Health Care Equity Research Award recipients Rachel Forman, MD, and Adys Mendizabal, MD, MS. Attendees can claim three CME credits. All attendees are invited to stay after the symposium to connect with their colleagues over snacks and refreshments.
Don’t miss Java, Juice & Jobs on
Tuesday!
Wake up to a flavorful Annual Meeting favorite tomorrow from 7:00 a.m. to 9:00 a.m. in the Marriott Marquis Grand Ballroom 7–9. This Neurology Career Center event features networking opportunities with your peers and neurology hiring managers, 40+ employer booths, breakfast, and free giveaways while supplies last.
Start your day at this fun event offering something for everyone—including a visit from Sarah Bellum™. Arrive early for a chance to get a gift bag!
For more information, visit AAN.com/AM and search for Java, Juice & Jobs.
Session sponsored by:
Pioneering Gene Therapy in Neurodegenerative Disease
Our goal is to use the advanced technology of gene therapy to impact disease progression in individuals with Parkinson’s disease and multiple system atrophy. Gene therapy may provide neuroprotection and neurorestoration of dopaminergic neurons.
DISCOVER THE DIAGNOSTIC POWER OF SKIN
Gain key pathological insights for patients facing challenging diagnoses using three simple skin biopsies. The Syn-One Test provides visual evidence of a synucleinopathy by detecting abnormal synuclein within cutaneous nerve fibers, helping clinicians diagnose Parkinson’s disease, dementia with Lewy bodies, and related disorders.
With >95% sensitivity and specificity1, the Syn-One Test has been shown to increase diagnostic confidence and support more personalized treatment plans.2
One half of the AAN’s mission is to promote brain health for all—and of course, a massive part of that mission will be achieved in the clinic. Attend “Hot Topics in Clinical Practice: The Neurologist’s Role in Promoting Brain Health” from 1:00 p.m. to 3:00 p.m. today in 31AB for a review focusing on four pillars of brain health: science, patient care, patient education, and policy. This session will be directed by child neurology expert Rana R. Said, MD, FAAN, who serves on the AAN’s Brain Health Committee.
Visualize Abnormal Synuclein in Dermal Nerves
Learn more about the Syn-One Test at cndlifesciences.com
Today’s power-packed AAN Conferences mobile app tip: connect with presenters
The powerful AAN Conferences mobile app makes connecting with presenters, accessing program materials, catching posters you might have missed, and even claiming your CME easier than ever. Here’s how:
• Join the conversation with presenters: Use the app or desktop platform to submit your question for presenters to see and respond to in real time.
• Simply select the “Documents” button within the program listing. Program materials are available at the discretion of the presenter.
• Complete evaluations and claim your CME. Click the link in the session you visited, or the “Claim CME” button on the dashboard or left-hand navigation.
• View the online poster gallery from the main dashboard or left-hand navigation. Posters will only be available once they have been presented in the poster hall.
Bonus tip:
Be sure to allow push notifications in the AAN Conferences mobile app for timely updates throughout the Annual Meeting!
Experts will discuss surgical treatment of intracerebral hemorrhage at today’s Neuroscience in the Clinic session
Directors H. E. Hinson, MD, MCR, FAAN, and Matthew Potts, MD, will be joined by expert faculty Fernanda Carvalho Poyraz, MD, PhD, and abstract presenters Brandon Lucke-Wold, MD, PhD, and Ashley Lopez, DO, in a discussion about surgical management of non-traumatic intracerebral hemorrhage (ICH) during today’s Neuroscience in the Clinic. The session will take place from 3:30 p.m. to 5:30 p.m. in 29CD. Presenters will explain how to classify the pathophysiology and patterns of hemorrhage, and provide insight into the surgical approaches. Participants should gain confidence in application of these new management strategies to their own patient populations, especially when to seek neurosurgical consultation.
“Recently, evidence from clinical trials supports surgical clot evacuation in spontaneous ICH as a treatment to improve outcomes,” said Hinson. “Our session will help neurologists navigate these new treatment options by selecting patients who might benefit the most from surgery. Attendees will learn both the evidence supporting surgery and how these minimally invasive techniques are done.”
The session will conclude with a panel discussion along with opportunity for questions. Attendees may claim two CME credits.
Hinson
Potts Carvalho Poyraz
Lucke-Wold Lopez
Late-breaking Science session starts this morning, highlights newest discoveries
Head on over to 6A from 11:15 a.m. to 12:45 p.m. for a review of the most timely, significant, and innovative research in neurology. Abstracts selected for Late-breaking Science presentations include key aspects of research conducted after the October 2024 abstract submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and publication. These previously unpublished abstracts contain timely, significant, and innovative content. Abstracts and Presenters:
11:15 a.m.–11:21 a.m.
Efficacy and Safety of Flexible-Dose Tavapadon, an Orally Administered, Once-Daily, Selective D1/D5 Partial Dopamine Agonist for the Treatment of Early Parkinson’s Disease
Presenter: Hubert H. Fernandez, MD, FAAN
11:21 a.m.–11:27 a.m.
Efficacy and Safety of Fixed-Dose Tavapadon, an Oral, Once-Daily, Selective D1/D5 Partial Dopamine Agonist for the Treatment of Early Parkinson’s Disease
Presenter: Rajesh Pahwa, MD, FAAN
11:27 a.m.–11:33 a.m.
Efficacy and Safety of AXS-05 in Alzheimer’s Disease
Agitation: A Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study
Presenter: George Grossberg, MD
11:33 a.m.–11: 39 a.m.
Intravenous Fosphenytoin Therapy for Acute Trigeminal Neuralgia: A Phase 3 Randomized Clinical Trial (IFT Study)
Presenter: Shusaku Noro, MD
11:39 a.m.–11:45 a.m.
A Holistic Spinal Cord Stimulation Approach to Treat Painful Diabetic Peripheral Neuropathy: The Inspire Study
Presenter: Gerardo Gutierrez, MD
11:45 a.m.–11:51 a.m.
Mi-Helper Transnasal Cooling for Acute Migraine
Treatment: A Prospective, Double-blind, Randomized, Sham-controlled, Decentralized Dosing Study
Presenter: Maryann Mays, MD, FAAN
11:51 a.m.–11:57 a.m.
Multi-ancestry Genome-wide Analysis of 90,600 Migraine
Cases in US Veterans
Presenter: Xiao Michelle Androulakis, MD
11:57 a.m.–12:03 p.m.
Safety, Tolerability and Efficacy of ALMB-0166 in the Patients with Acute Spine Cord Injury (SCI): A Multicenter, Randomized, Placebo-controlled, Phase I/II Study
Presenter: Jinqian Liang, MD
12:03 p.m.–12:09 p.m.
ARIA Risk Factors and Management Experience in Donanemab Clinical Trials in Early Symptomatic Alzheimer’s Disease
Presenter: Alessandro Biffi, MD
Poster Q&A will take place from 12:09 p.m. to 12:45 p.m.
Tough on Duchenne.
So it’s easier to be him.
AGAMREE® Is a Novel Corticosteroid
• Unique chemical structure: Developed to uncouple anti-inflammatory effects and certain corticosteroid-mediated adverse effects1,2
• Proven efficacy: Improved muscle strength and motor function3,4
• Well tolerated: Established safety and tolerability profile in clinical studies3,4
GAVEN
A real AGAMREE patient
LEARN MORE at AGAMREEhcp.com
AGAMREE is FDA approved for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older3 Visit Booth 807 at the 2025 AAN Annual Meeting
SELECT IMPORTANT SAFETY INFORMATION
Warnings & Precautions
• Alterations in Endocrine Function: Monitor patients receiving AGAMREE for Cushing’s syndrome, hyperglycemia, and adrenal insufficiency after AGAMREE withdrawal. In addition, patients with hypopituitarism, primary adrenal insufficiency or congenital adrenal hyperplasia, altered thyroid function, or pheochromocytoma may be at increased risk for adverse endocrine events. Acute adrenal insufficiency can occur if AGAMREE is withdrawn abruptly, and could be fatal.
• Immunosuppression and Increased Risk of Infection: Use of corticosteroids, including AGAMREE, increases the risk of new infection, exacerbation of existing infections, dissemination, and reactivation or exacerbation of latent infection and may mask some signs of infection; these infections can be severe, and at times fatal.
• Alterations in Cardiovascular/Renal Function: Monitor for elevated blood pressure and monitor sodium and potassium levels in patients chronically treated with AGAMREE.
• Gastrointestinal Perforation: Use of corticosteroids increases the risk of gastrointestinal perforation in patients with certain gastrointestinal disorders, such as active or latent peptic ulcers, diverticulitis, fresh
intestinal anastomoses, and non-specific ulcerative colitis. Signs and symptoms may be masked.
• Behavioral and Mood Disturbances: Potentially severe psychiatric adverse reactions may occur with systemic corticosteroids, including AGAMREE, and may include hypomanic or manic symptoms (eg, euphoria, insomnia, mood swings) during treatment and depressive episodes after discontinuation of treatment.
• Effects on Bones: Prolonged use of corticosteroids, such as AGAMREE, can lead to osteoporosis, which can predispose patients to vertebral and long bone fractures. Monitor bone mineral density in patients on long-term treatment with AGAMREE.
• Ophthalmic Effects: The use of corticosteroids, such as AGAMREE, may increase the risk of cataracts, ocular infections, and glaucoma. Monitor intraocular pressure if treatment with AGAMREE is continued for more than 6 weeks.
• Vaccination: Do not administer live-attenuated or live vaccines to patients receiving AGAMREE. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting AGAMREE.
Please see Brief Summary of full Prescribing Information on the next page.
References: 1. Liu X, et al. Proc Natl Acad Sci USA. 2020;117(39):24285-24293. 2. Heier CR, et al. EMBO Mol Med. 2013;5(10):1569-1585. 3. AGAMREE (vamorolone) Oral Suspension [prescribing information]. Catalyst Pharmaceuticals, Inc.; 2025. 4. Guglieri M, et al. JAMA Neurol. 2022;79(10):1005-1014.
AGAMREE® (vamorolone) oral suspension
BRIEF SUMMARY – See Full Prescribing Information at AGAMREEhcp.com
Initial U.S. Approval: 2023
INDICATIONS AND USAGE
AGAMREE is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
DOSAGE AND ADMINISTRATION
Dosing Information
The recommended dosage of AGAMREE is 6 mg/ kg taken orally once daily preferably with a meal, up to a maximum daily dosage of 300 mg for patients weighing more than 50 kg.
Some patients may respond to a dose of 2 mg/kg daily. Doses may be titrated down to 2 mg/kg/day as needed, based on individual tolerability.
Discontinuation
Dosage of AGAMREE must be decreased gradually if the drug has been administered for more than one week.
CONTRAINDICATIONS
AGAMREE is contraindicated in patients with known hypersensitivity to vamorolone or to any of the inactive ingredients of AGAMREE. Instances of hypersensitivity, including anaphylaxis, have occurred in patients receiving corticosteroid therapy.
WARNINGS AND PRECAUTIONS
Alterations in Endocrine Function
Corticosteroids, such as AGAMREE, can cause serious and life-threatening alterations in endocrine function, especially with chronic use. Monitor patients receiving AGAMREE for Cushing’s syndrome, hyperglycemia, and adrenal insufficiency after AGAMREE withdrawal. In addition, patients with hypopituitarism, primary adrenal insufficiency or congenital adrenal hyperplasia, altered thyroid function, or pheochromocytoma may be at increased risk for adverse endocrine events.
Acute adrenal insufficiency can occur if AGAMREE is withdrawn abruptly, and could be fatal. The risk of adrenal insufficiency is reduced by gradually tapering the dose when withdrawing treatment. For patients already taking corticosteroids during times of stress, the dosage may need to be increased.
Immunosuppression and Increased Risk of Infection
Corticosteroids, including AGAMREE, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can reduce resistance to new infections, exacerbate existing infections, increase the risk of disseminated infections, increase the risk of reactivation or exacerbation of latent infections, and mask some signs of infection. Corticosteroid-associated infections can be mild but can be severe, and at times fatal.
The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider AGAMREE withdrawal or dosage reduction as needed.
Tuberculosis
If AGAMREE is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged AGAMREE therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis.
Varicella Zoster and Measles Viral Infections
Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including AGAMREE. In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles.
• If an AGAMREE-treated patient is exposed to varicella, prophylaxis with varicella zoster immunoglobulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.
• If an AGAMREE-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.
Hepatitis B Virus Reactivation
Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including AGAMREE. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection.
Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with AGAMREE. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in
managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.
Fungal Infections
Corticosteroids, including AGAMREE, may exacerbate systemic fungal infections; therefore, avoid AGAMREE use in the presence of such infections unless AGAMREE is needed to control drug reactions. For patients on chronic AGAMREE therapy who develop systemic fungal infections, AGAMREE withdrawal or dosage reduction is recommended.
Amebiasis
Corticosteroids, including AGAMREE, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating AGAMREE in any patients who have spent time in the tropics or patients with unexplained diarrhea.
Strongyloides Infestation
Corticosteroids, including AGAMREE, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.
Cerebral Malaria
Avoid corticosteroids, including AGAMREE, in patients with cerebral malaria.
Alterations in Cardiovascular/Renal Function
Corticosteroids, including AGAMREE, can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium and calcium. Monitor blood pressure and assess for signs and symptoms of volume overload. Monitor serum potassium levels.
AGAMREE should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. Literature reports suggest an association between use of corticosteroids and left free wall rupture after a recent myocardial infarction; therefore, therapy with AGAMREE should be used with great caution in these patients.
Gastrointestinal Perforation
There is an increased risk of gastrointestinal perforation with the use of corticosteroids in patients with certain gastrointestinal disorders, such as active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis. Signs of gastrointestinal perforation, such as peritoneal irritation, may be masked in patients receiving corticosteroids.
Avoid AGAMREE if there is a probability of impending perforation, abscess, or other pyogenic infections; diverticulitis; fresh intestinal anastomoses; or active or latent peptic ulcer.
Behavioral and Mood Disturbances
Potentially severe psychiatric adverse reactions may occur with systemic corticosteroids, including AGAMREE. Symptoms typically emerge within a few days or weeks of starting treatment and may be doserelated. These reactions may improve after either dose reduction or withdrawal, although pharmacologic treatment may be necessary.
Inform patients or caregivers of the potential for behavioral and mood changes and encourage them to seek medical attention if psychiatric symptoms develop, especially if depressed mood or suicidal ideation is suspected.
Effects on Bones
Decreased Bone Mineral Density
Corticosteroids, such as AGAMREE, decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of bone loss at any age. Bone loss can predispose patients to vertebral and long bone fractures.
Consider a patient’s risk of osteoporosis before initiating corticosteroid therapy. Monitor bone mineral density in patients on long-term treatment with AGAMREE.
Avascular Necrosis
Corticosteroids may cause avascular necrosis.
Ophthalmic Effects
The use of corticosteroids, such as AGAMREE, may produce posterior subcapsular cataracts.
Corticosteroids may also cause glaucoma with possible damage to the optic nerves, and may increase the risk of secondary ocular infections caused by bacteria, fungi, or viruses. Corticosteroids are not recommended for patients with active ocular herpes simplex. Intraocular pressure may become elevated in some patients taking corticosteroids. If treatment with AGAMREE is continued for more than 6 weeks, monitor intraocular pressure.
Immunizations
Administer all immunizations according to immunization guidelines prior to starting AGAMREE. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting AGAMREE. Patients on AGAMREE may receive concurrent vaccinations, except for live-attenuated or live vaccines.
Effects on Growth and Development
Long-term use of corticosteroids, including AGAMREE, can have negative effects on growth and development in children.
Myopathy
Patients receiving corticosteroids and concomitant therapy with neuromuscular blocking agents (e.g., pancuronium) or patients with disorders of neuromuscular transmission (e.g., myasthenia gravis) may be at increased risk of developing acute myopathy. This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.
Kaposi’s Sarcoma
Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma.
Thromboembolic Events
Observational studies have shown an increased risk of thromboembolism (including venous thromboembolism) particularly with higher cumulative doses of corticosteroids. It is unclear if risk differs by daily dose or duration of use. Use AGAMREE with caution in patients who have or may be predisposed to thromboembolic disorders.
Anaphylaxis
Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy.
ADVERSE REACTIONS
The following serious adverse reactions are discussed in more detail in other sections:
• Alterations in Endocrine Function
• Immunosuppression and Increased Risk of Infection
• Alterations in Cardiovascular/Renal Function
• Gastrointestinal Perforation
• Behavioral and Mood Disturbances
• Effects on Bones
• Ophthalmic Effects
• Immunizations
• Effects on Growth and Development
• Myopathy
• Kaposi’s Sarcoma
• Thromboembolic Events
• Anaphylaxis
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Common Adverse Reactions in Clinical Studies
Table 1 lists the adverse reactions that occurred in ≥5% of the patients treated with AGAMREE 6 mg/kg/ day (N=28) or AGAMREE 2 mg/kg/day (N=30) and that occurred more frequently than in the patients who received placebo (N=29) in Study 1, which was 24 weeks and included patients with DMD between the ages of 4 and 7 years.
Table 1: Adverse Reactions in Patients with DMD that Occurred in ≥5% of Patients Treated with AGAMREE and More Frequently than in Patients Who Received Placebo During 24 Weeks (Study 1)
USE IN SPECIFIC POPULATIONS
Pregnancy
Risk Summary
AGAMREE is indicated for use for the treatment of DMD, which is a disease of young male patients. However, corticosteroids in general should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. There are no data on the use of AGAMREE during pregnancy.
Animal reproduction studies have not been conducted with AGAMREE.
Lactation
Risk Summary
There are no data on the presence of vamorolone in human milk or the effects on milk production. AGAMREE is indicated for use for the treatment of DMD, which is a disease of young male patients. However, systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need and any potential adverse effects on the breastfed infant.
Pediatric Use
The safety and effectiveness of AGAMREE for the treatment of DMD have been established in patients 2 years of age and older. Use of AGAMREE in pediatric patients is supported by a multicenter, randomized, double-blind, placebo- and active-controlled study in 121 males 4 to less than 7 years of age. Use of AGAMREE in patients 2 years to less than 4 years of age and 7 to less than 18 years of age is supported by findings of efficacy and safety in patients 4 to less than 7 years of age with DMD, and by pharmacokinetic and safety data from patients 2 to 4 years of age and 7 to less than 18 years of age.
The safety and effectiveness in pediatric patients below the age of 2 years have not been established. Geriatric Use
DMD is largely a disease of children and young adults; therefore, there is no geriatric experience with AGAMREE.
Hepatic Impairment
Moderate hepatic impairment increases vamorolone exposure. Reduce the AGAMREE dosage in patients with mild to moderate hepatic impairment. There is no clinical experience with AGAMREE in patients with severe hepatic impairment, and a dosing recommendation cannot be provided for patients with severe hepatic impairment.
CLINICAL PHARMACOLOGY
Mechanism of Action
Vamorolone is a corticosteroid that acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which vamorolone exerts its effect in patients with DMD is unknown.
Pharmacodynamics
Vamorolone produced a dose-dependent decrease in morning cortisol levels in the clinical studies. Treatment with corticosteroids is associated with a suppression of endogenous cortisol concentrations and an impairment of the hypothalamus-pituitaryadrenal (HPA) axis function. A dose-dependent increase in leukocyte counts and lymphocyte counts was observed in clinical studies with vamorolone.
Cardiac Electrophysiology
Vamorolone does not cause a mean increase in the QTc interval >20 milliseconds (ms) at 1.6 times the approved recommended dose.
See full Prescribing Information available at AGAMREEhcp.com.
1Includes the following adverse reactions that occurred more frequently in the AGAMREE group than in placebo: abnormal behavior, aggression, agitation, anxiety, irritability, mood altered, sleep disorder, and stereotypy.
In a separate open-label safety study of pediatric patients aged 2 to less than 4 years (n=16) and pediatric patients aged 7 to less than 18 years (n=16) with DMD, adverse reactions were similar to those seen in the Study 1 pediatric patients.
DRUG INTERACTIONS
Effect of Other Drugs on Vamorolone
Co-administration of AGAMREE with itraconazole, a strong CYP3A4 inhibitor, increases vamorolone exposure. Reduce the dosage of AGAMREE in patients when strong CYP3A4 inhibitors are used concomitantly. No dosage adjustments are required when AGAMREE is concomitantly administered with moderate or weak CYP3A4 inhibitors.
AAN honors longtime leader, volunteer with 2025 President’s Award
After over two decades of leadership with the AAN, Janis Miyasaki, MD, MEd, FRCPC, FAAN, is being honored with the Academy’s prestigious President’s Award. The award honors outstanding service to the AAN and to the profession of neurology—two things that Miyasaki has given in spades.
“Selecting Dr. Miyasaki for this award was one of the easiest decisions I’ve made as AAN president,” said Carlayne E. Jackson, MD, FAAN, who has worked alongside Miyasaki in Academy leadership for more than a decade.
“She is a wise, creative, and devoted leader of this organization, a trusted colleague, and an excellent neurologist—one who has done so much good both directly, through her practice and teaching, and indirectly, through her tireless work on AAN resources.”
Miyasaki has served on nearly every major Academy committee—Brain Health, Meeting Management, Education, Practice, and more— and countless subcommittees and work groups, including those on practice improvement, therapeutics and technology, digital strategy, and wellness. She has also been an invaluable voice in important initiatives on the AAN’s value of Diversity, Equity, and Inclusion, serving on the Special Commission on Systemic Racism and Inequalities in Society, the Diversity Work Group of the Board of Directors, and the Advancing Women in Academics Subcommittee.
Most prominently, Miyasaki is a longtime member of the AAN Board of Directors. She was first elected to the Board as a director in 2011 and went on to serve as Treasurer and then Vice President, becoming a trusted leader both in the AAN and in her field.
“The AAN has helped me grow, make friends and colleagues, and have a career that I could never have dreamed of,” Miyasaki said. “I am so fortunate to have been Vice President and to have had so many opportunities in the AAN, and I’m grateful for the recognition of the President’s Award.”
Miyasaki is Department Head of Clinical Neurosciences at the University of Alberta and Alberta Health Services, where she was also the Department of Medicine’s first Director of Equity, Diversity, and Inclusion. She is an active clinical researcher and mentor in movement disorders, physician wellness, and equity. Her other roles have included director of education for neurology for four hospitals; member of the board of trustees for the University Health Network; president of the Medical
Staff Association; president of the Canadian Movement Disorders Group; deputy PhysicianIn-Chief at Toronto Western Hospital, and Associate Clinical Director of the Movement Disorders Centre at Toronto Western Hospital. In 2007, she initiated the first neurologist-led palliative care program for movement disorders in the world. Her accolades for 2025 alone include another AAN honor, the Movement Disorders Research Award, and the King Charles III Coronation Medal.
It was in 2000, however, that Miyasaki first became involved in the AAN’s work. As a specialist in movement disorders, she was invited to write a guideline on Parkinson’s disease.
“At the time, evidence-based medicine was relatively new,” Miyasaki said. “There was skepticism by the medical profession around it, and there wasn’t a clear methodology around how to develop evidence-based guidelines, which the AAN was trying to do.”
Miyasaki and her colleagues followed a lengthy, rigorous process and examined all of the evidence they could find on drugs used for management of Parkinson’s disease, publishing their work in 2002.
“Our guideline was controversial at the time, because it said something different than what many people expected,” she said. “There was also some controversy around guidelines themselves and whether they imposed practice choices on physicians.”
Newly a faculty member at her alma mater, the University of Toronto, Miyasaki had just completed four years in private practice—and she had some ideas on how guidelines could be better received. Her first change was to provide one-page summaries for doctors and patients, turning dense, academic, and time-consuming reading into ready-to-use insights: “I didn’t always have time in private practice to read journals from cover to cover,” she said.
Her other idea was more complicated, involving many hours of work and outreach on her part: speaking to state neurology society meetings to promote evidence-based medicine.
“I think I’ve been all over Virginia, Kentucky, North Carolina, Texas, and Washington,” she said. “Very lovely states. I was pretty open in my naivete to say, ‘Tell me what you hate about guidelines,’ and believe me, they did tell me. It was a chance to explain that guidelines were not meant to take away physicians’ discretion,
but to synthesize hundreds and now thousands of papers into the best evidence to help guide care.”
Miyasaki grew increasingly involved in guideline development at the AAN, becoming a member of the Technology Assessment Subcommittee (a precursor to the Guidelines Subcommittee) and then its chair. She watched as guidelines went from a small area of the AAN—one that needed extensive work from the small group of volunteers involved—to one of the top reasons why members choose to belong.
“It was literally hundreds of hours of work to create one guideline, and it was done through the sheer will of the physician volunteers who would guide it along,” Miyasaki recalled of those early days. “To have that kind of commitment to your profession is really special.”
A subcommittee role became a committee role, became an elected Board of Directors role, became more committee roles and leadership positions. As her contributions at the AAN grew, Miyasaki found herself connecting with other members and seeing that—despite their differences in locations and practice settings— they were facing many of the same challenges.
“When you’re feeling alone in your career, or facing burnout, the connectedness you can find in the AAN is so important,” she said. “When you participate in this community, you find your people—a group of amazing, enthusiastic people who think the brain is the coolest thing ever. You see that other people are facing the same challenges and that we’re going to get through it.”
After decades of service at the AAN, Miyasaki’s professional life has reached heights that she didn’t previously think possible. More importantly, however, she has found a “home” where her passion for the field is recognized and answered.
She said, “For the hundreds of members who volunteer their time and hard work at the AAN, neurology isn’t just a job—it’s a calling.”
LOOKING TO HONE YOUR LEADERSHIP SKILLS? CHECK OUT LEADERSHIP UNIVERSITY!
Leadership development is personal development, so take time to invest in yourself. Stop by the Leadership University Hub in 5B to discover how you can meet your professional development goals no matter the time of year—now that Leadership University is available at your convenience in the Online Learning Center! You’ll also have the opportunity to hear from world-renowned consultants and physician leaders throughout the week.
Applications open for AAN Leadership Programs—apply by May 15
Want to take your leadership skills to the next level? Applications are now open for three prestigious, all-expenses-paid AAN Leadership Programs that offer executive leadership education, collaboration and networking with peers, and one-to-one coaching and mentorship. There are no programs quite like these! Learn more and apply at AAN.com/Lead.
• Diversity Leadership Program: Develops leadership skills in members from groups that are underrepresented in neurology.
• Emerging Leaders Program: Engages talented early-career members who have the disposition to lead and are interested in future roles within the AAN and the field of neurology.
• Practice Leadership Program: Develops leadership skills in solo and small practitioners while accommodating their busy schedules.
Congratulations to our 2024 FAAN members!
The AAN’s esteemed Fellow status (FAAN) recognizes members’ exemplary work and achievements in the neurosciences, clinical practice or academic/administrative neurology, the AAN, and their communities. Visit the FAAN wall outside room 30 to see the names and photos of members who achieved this status in 2024!
TODAY’S HUB HEROICS
Unleash your inner hero at Annual Meeting Hubs!
Prepare to step out of the traditional classroom into the dynamic world of Annual Meeting Hubs. These extraordinary learning opportunities are your chance to connect, collaborate, and learn through unconventional methods. Hubs will empower you to bring fresh perspectives and innovative approaches back to your career, patients, and community. Get ready to soar to new heights and make a heroic impact!
Here are today’s highlights:
Academic
Hub
27 Lobby
What Is the AAN Doing to Help Academic Neurology?
11:00 a.m.–11:45 a.m.
How can the AAN help your academic neurology department thrive? Learn about AAN programs and offerings designed to help academic neurology departments and academic neurologists, both scientists and educators.
A House United: The Art of Being
a Division Chief
4:00 p.m.–5:00 p.m.
Division chiefs are a crucial element to advance the mission of neurology departments and influence their members’ careers. This program is designed to introduce individuals aspiring to or holding the position of division chief with the leadership and management skills to effectively oversee a division within a department, focusing on areas like philanthropy, operational efficiency, team building, decision-making, and conflict management.
Practice and Policy Hub 20D Lobby
Wait, Wait, Do Tell Me: Bridging the Gap Between In-office and Telemedicine Neurological Exams
11:30 a.m.–12:30 p.m.
With the help of video demonstrations, learn what is possible during a real-time audiovisual telehealth exam and understand common misconceptions about what can be evaluated in various settings. Gain insight into completing both in-office and telemedicine exams, applying exam findings, and using appropriate testing to establish a diagnosis.
Trainee Hub
Sails Pavilion: Cityside Student Interest Group in Neurology (SIGN) Meeting
11:30 a.m.–1:00 p.m.
SIGN student and faculty leadership will have opportunity to learn chapters, with time
Note that box lunches starting at 11:00 a.m. hall; feel free to bring lunch to this meeting.
HeadTalks D Lobby
NeuroTails: Consults from the Zoo
11:00 a.m.–11:45 a.m.
Get ready to dive into the captivating world of animal neurology with Ann H. Tilton, FAAN, and become a true hero for our animal companions! You’ll embark on a thrilling journey to discover that animals, just like humans, can experience neurological conditions, and become a super sleuth, uncovering the fascinating diagnostic tools and treatment approaches used to help our furry friends manage these conditions.
Dendritic
Dare
4:30 p.m.–5:30 p.m.
From the masterminds behind Neurdle, Endowed Chairs, and Charcot’d Breakers comes an epic, action-packed game show! This ‘Double Dare’-like showdown will put your neurology knowledge, word-finding superpowers, coordination skills, and Witzelsucht to the ultimate test.
Hub Pavilion: Interest Neurology Meeting p.m. faculty have the learn from other for networking. lunches are available a.m. in the exhibit bring your box meeting.
MD, thrilling
Research Hub 11B
Leveraging REDCap and Clinical Data Collection Systems
2:00 p.m.–2:30 p.m.
Discover how to use REDCap and other clinical data collection systems in neurology. Given the rapidly evolving landscape of data management and analysis, the effective use of these tools is crucial in advancing research and advancing patient outcomes.
Innovation Hub Exhibit Hall BCD
Brainstorm-a-thon: A Group Competition for the Innovator in All of Us
4:00 p.m.–5:30 p.m.
Which team will prevail in this fast-paced challenge, where groups work together to brainstorm and present a solution to a problem they receive on-site?
Wellness Hub
Sails Pavilion: Bayside
Social Hour
2:00 p.m.–3:00 p.m.
Salsa Dance
3:00 p.m.–4:00 p.m.
Relax and enjoy light refreshments with your colleagues during this social hour focused on well-being, followed by a salsa dance workshop!
Leadership University 5B
Women in Leadership: Enhancing Negotiation Skills
12:00 p.m.–1:00 p.m.
Take away strategies and tips to improve your negotiation skills.
Upcoming Publications Talks
Today
Public Education to Promote Brain Health for All— A Panel of Brain & Life® Editorial Board Members
Publications Area (Sails Pavilion: Bayside)
11:30 a.m.–12:00 p.m.
Sarah Song, MD, MPH, FAAN; David C. Spencer, MD, FAAN; Daniel José Correa, MD, MSc, FAAN; Jori Fleisher, MD, MSCE, FAAN; Michael S. Jaffee, MD, FANA, FAAN; Joel Salinas, MD, MBA, MSc, FAAN
Brain & Life® is the AAN’s connection to the public and aims to bring a variety of stories to light. We seek to amplify patient stories, to share new research, to advocate for patients and their caretakers, and to educate the public about brain health. Come and speak to some of the Editorial Board members to brainstorm ways to utilize Brain & Life to share scientifically sound information with the public.
How to Publish Your Teaching Scholarship in Neurology®: Tips from the Neurology® Education Editorial Board
Trainee Hub (Sails Pavilion: Cityside)
12:00 p.m.–12:30 p.m.
Roy E. Strowd III, MD, MEd, MS, FAAN; Brendan Huang, MD; Frédérique Ouellet, MD; Jorge Patino, MD
Enjoy a meet and greet with the Neurology® Education Trainee Editorial Board.
Physician as Patient: Interview with Neurologists Living with a Neurologic Condition
Innovation Hub (Exhibit Hall BCD)
12:20 p.m.–1:20 p.m.
Daniel José Correa, MD, MSc, FAAN; Katherine B. Peters, MD, PhD, FAAN; Joel Salinas, MD, MBA, MSc, FAAN; Andrea Lendaris, MD, MS; Andrew M. Southerland, MD, MSc, FAAN; Eric J. Seachrist, MD
Watch a live Brain & Life® podcast recording and interview with Salinas, Seachrist, and Lendaris, who live and practice neurology with their own neurological condition(s) and neurodiverse perspective. Explore how their experiences serve as a window into the patient and community perspective.
Neurogenetics Through the Decade: A Journey of Progress and Insight Room 28E
1:00 p.m.–2:00 p.m.
Stefan M. Pulst, MD, FAHA, FAAN; José G. Merino, MD, MPhil, FAHA, FAAN; Suman Jayadev, MD
Neurology® Podcast and Neurology Minute®: 18 Years of Audio Excellence and Educational Impact
Publications Area (Sails Pavilion: Bayside)
1:30 p.m.– 2:30 p.m.
Andrew M. Southerland, MD, FAAN; Stacey L. Clardy, MD, PhD, FAAN; Jeffrey B. Ratliff, MD, FAAN; Teshamae Monteith, MD, FAAN; and contributors
Join the editors for an exclusive behind-the-scenes look at what it takes to produce as much weekly audio content as a bustling newsroom. Discover the secrets behind the Neurology® Podcast’s 18 years of success and the significant impact it has had on neurology education. Don’t miss the chance to learn how to get involved and enjoy the latest podcast swag!
Neuroimmunology & Neuroinflammation 2015-2025: A View from 30,000 Feet
Room 28E
2:00 p.m.–3:00 p.m.
Josep O. Dalmau, MD, PhD, FAAN; Richard M. Ransohoff, MD; Scott S. Zamvil, MD, PhD, FAAN; José G. Merino, MD, MPhil, FAHA, FAAN
Tuesday
Ted Burns – A Legacy of Humanism and Innovation
Innovations Hub (Exhibit Hall BCD)
12:50 p.m.–1:20 p.m.
Stacey L. Clardy, MD, PhD, FAAN; Jeffrey B. Ratliff, MD, FAAN; Andrew M. Southerland, MD, MSc, FAAN; Mehari Gebreyohanns, MD, FAAN; Howard P Goodkin, MD, PhD; Brett M. Kissela, MD, MS, FAAN; and contributors
Discuss the legacy of innovator and podcast pioneer Ted Burns, honor past and present recipients of the Ted Burns Humanism Award, and explore the meaning and importance of humanism.
Patient Resource Panel
Publications Area (Sails Pavilion: Bayside)
2:30 p.m.–3:00 p.m.
Sarah Song, MD, MPH, FAAN; David C. Spencer, MD, FAAN; Joseph I. Sirven, MD, FAAN; Daniel José Correa, MD, MSc, FAAN; Katherine B. Peters, MD, PhD, FAAN
Brain & Life is a lifeline for patients who are looking for stories like theirs and resources to share with each other and their communities. Come learn how patients can learn from each other, and how we at Brain & Life can help enrich and enhance our patients’ lives.
Listen to Learn: Continuum® Audio and Continuum Aloud Panel
Publications Area (Sails Pavilion: Bayside)
3:30 p.m.–4:00 p.m.
Lyell K. Jones, MD, FAAN; Teshamae Monteith, MD, FAAN; Katie Grouse, MD, FAAN; Michael Kentris, DO; Michelle Goodwin, MD
How do you learn? Continuum® Audio interviewers and Continuum Aloud narrators weigh in on creating engaging audio content and catering to an audience that prefers to listen to learn.
Meet the Neurology Incredibles!
The AAN has an incredible family of publications to keep you super savvy and powerfully patient-centered—from essentials like Neurology® to the newest addition, Neurology® Open Access. Visit the AAN Publications booth in the Sails Pavilion to see for yourself.
Neurology®: The quintessential neurology journal, included for free in most AAN membership types. Find the latest peerreviewed original clinical research articles, AAN position papers and clinical guidelines, editorials, and reviews that enhance the field of neurology and influence patient care. Earn CME credit by reading select articles and taking exams online.
Neurology® Family: Dive even deeper with specialty journals like Neurology® Clinical Practice, Neurology® Neuroimmunology & Neuroinflammation, Neurology® Genetics, and Neurology® Education, or browse the all-new Neurology® Open Access for peerreviewed articles, reviews, case reports, and study protocols relevant to clinicians, clinical researchers, policy makers, and patients.
Continuum: Lifelong Learning in Neurology®: The ultimate companion for any neurology career stage, with CME credits available. Each bimonthly issue contains in-depth clinically oriented reviews by expert authors focused around a single topic area in neurology.
Neurology Today®: Stay up to date with the AAN’s official news source, reporting on breaking news, issues, and trends in neurology. Published in print twice a month.
Brain & Life®: A free magazine, website, and book series for patients, caregivers, and anyone interested in brain health. Articles connect readers with stories of people living with brain disease, the latest research, and perspectives on brain health not found anywhere else.
Podcasts are available from Neurology® , Continuum®, Brain & Life, and more!
EXHIBIT HALL PRESENTATION
Innovative Insights: Clinical and Analytical Performance of the Plasma p-Tau217 Quanterix SP-X Chemiluminescent Assay
Monday, April 7 3:30 pm
Located Next to the Exhibit Hall Meeting Suites
Kelly Doyle, PhD, DABCC, FADLM
Medical Director: Special Chemistry and Endocrinology
Associate Professor of Pathology (Clinical)
University of Utah School of Medicine
PLEASE JOIN US FOR A PRESENTATION BY:
Transforming Alzheimer’s Disease
Diagnosis with the PrecivityAD2™ Blood Test
WHEN: Monday, April 7, 2025 | @ 3 - 3:20 PM
WHERE: Exhibit Hall
SESSION HIGHLIGHTS:
Learn the characteristics of a high-performing blood biomarker (BBM) test in the evaluation of patients 55 years and older with symptoms of cognitive impairment.
Learn about the clinical utility of a BBM test for brain amyloid pathology in the care pathway.
VOICES OF THE ANNUAL MEETING
What do you enjoy about neurology?
What are you looking forward to at the Annual Meeting this year?
Mainly networking. It’s a great opportunity to meet former and future colleagues. A lot of things happen here—a lot of interviews, a lot of projects start from discussions over coffee or lunch here. The other thing I’m looking forward to is meeting pioneers in the field and exploring where things are heading in different subspecialities in neurology that I’m not as involved in.
What led you to choose neurology?
Neurology is one of those fields where patients are at a truly disadvantaged position. It’s tough to seek care when you have neurological functions preventing you from that. In neurology, you’re not just treating the illness, but treating the patient. There are social, mental, and financial challenges that come with a lot of neurological illnesses, and being able to be involved in my patients’ lives and help them on different levels is something that attracted me to neurology.
Majed Alomar, MBBS
I love that there’s so much that we don’t understand. I think it is a field that is built with so many curiosities, and I think even after all of these years of trying to learn and understand, there’s so much more that we don’t know. And I think I just really like hard things!
Madeline A. Chadehumbe, MD, FAAN
How I Treat CIDP
Speaker: Suraj Muley, MD
Professor of Neurology, University of Arizona
Bob Bové Neuroscience Institute Scottsdale, Arizona
Accessing Annual Meeting content is super flexible with 2025 Annual Meeting On Demand—and it’s not too late to bundle it with your meeting registration to save up to 55% on regular pricing. With Annual Meeting On Demand, you’ll be able to travel back in time to most session recordings and even have the ability to claim 375+ CME through March 1, 2026!
Contact aanamsupport@cmrus.com by May 7, 2025, or visit the registration area in the convention center to take advantage of these savings.
25 Annual Meeting Demand On
Helpful Hints for Heroes Helpful Hints for Heroes
To reach these links in a flash, go to AAN.com/QuickLinks.
Attendee lunch and Networking Crawl
Attendee lunch is included in your registration fee and served from 11:30 a.m. to 1:30 p.m. today in the exhibit hall. Lunches are served in compostable boxes to help with sustainability efforts.
Swoop in for the Exhibit Hall Networking
Crawl from 4:00 p.m. to 6:00 p.m. in the exhibit hall for a walking food tour around the hall to discover new cuisines and new contacts!
Program slides available online
Slides are available online only at AAN.com/Materials or through the AAN Conferences mobile app. You can access program materials through March 1, 2026. (Please note that availability of materials is at the discretion of the specific speaker. Not all sessions will have materials.)
Want more time to review programs?
Add Annual Meeting On Demand to your registration now to save up to 55% and to extend your access to session recordings through March 1, 2026. Check the back of your badge to see if you already have Annual Meeting On Demand. If not, head to registration or email aanamsupport@cmrus.com by May 7, 2025, to add it to your registration.
Shuttle information
Check the AAN Conference mobile app and Room Locator for information on shuttle service to select hotels within the AAN housing block. Have questions? Call (877) 899-0986.
Submit evaluations for CME
Complete your evaluations by May 7, 2025 (or March 1, 2026, with Annual Meeting On Demand) to get your CME credits by using the AAN Conferences Mobile App or by visiting AAN. com/AMCME . Transcripts will be available upon evaluation submission. AAN members can also access their transcript via NeuroTracker™ at AAN.com/NeuroTracker. Enter your 6-digit ID and password to log in.
AANTV Studio
Stop by the AANTV Studio at the top of the escalators by Ballroom 20 (the Plenary Session room) to witness live interviews being recorded for later broadcast on the desktop platform, TV monitors around the convention center, AAN.com/AANTV, and YouTube.
Access past content
Learn about sustainability
Sustainability efforts for the 2025 Annual Meeting include reducing the use of single-use materials—like signs— and using compostable or environmentally friendly inks wherever possible. Remember to recycle this issue of Annual Meeting Daily ! To learn more, visit AAN.com/FAQ .
Conference attendees have access to content on the online platform through May 7, 2025. Visit AAN.com/AMOnline and use your 6-digit ID and password to log in. It may take up to 48 hours after course completion for content to become available online.
Today’s Society Spotlight features European Committee for Treatment and
Research in Multiple Sclerosis
The AAN is partnering with the European Committee for Treatment and Research in Multiple Sclerosis to bring Annual Meeting attendees updates on the cutting-edge science of MS from speakers giving encore presentations of top research presented at the European Committee for Treatment and Research in Multiple Sclerosis meeting. The session will take place today from 1:00 p.m. to 3:00 p.m. in room 30C-E. Participants will hear about the most essential topics in MS, focusing on diagnosis and management and the latest updates and advancements.
Presentations and speakers include:
Novelties and Challenges of the Revised McDonald Diagnostic Criteria
Olga Ciccarelli, MD, PhD, FRCP
1:00 p.m.–1:20 p.m.
Current and Future Role of Advanced Imaging in MS
Cristina Granziera, MD, PhD
1:20 p.m.–1:40 p.m.
Aging and MS: Implications for Diagnosis and Treatment
Eva Strijbis, MD, PhD
1:40 p.m.–2:00 p.m.
PET Imaging to Understand Injury in MS
Laura Airas, MD, PhD
2:00 p.m.–2:20 p.m.
Perspectives for Neuroprotection and Remyelination
Bruno Stankoff, MD, PhD
2:20 p.m.–2:40 p.m.
Modern Concept and Treatment Advances for Progression in MS
Mar Tintoré, MD, PhD
2:40 p.m.–3:00 p.m.
Industry Therapeutic Update from Immunovant
Myasthenia Gravis –Evolving Therapeutic Landscape
Monday, April 7, 2025
LOCATION: San Diego Ballroom B Lobby Level Marriott Marquis San Diego Marina
SESSION TIME: 6:00 – 8:00 pm Dinner included
Meet the Program Faculty
Chair – Ri wak, MD, MS Yale School of Medicine
Srikanth Muppidi, MD
Stanford University
Mamatha Pasnoor,
University of Kansas Medical Center
Visit AAN Member Services in the Registration area to learn more and join today!
Celebrate these heroes of scientific discovery! 2025 AAN Scientific Award recipients
AAN NEURO-INFECTIOUS DISEASE AWARD
Sponsored by the American Academy of Neurology.
Kathryn Holroyd, MD
Columbia University Irving Medical Center, New York, NY
BHUWAN GARG HIGH SCHOOL NEUROSCIENCE RESEARCH PRIZE
Sponsored by the American Academy of Neurology and the Child Neurology Society.
Ella Saltstein
Byram Hills High School, Armonk, NY
BRUCE S. SCHOENBERG INTERNATIONAL AWARD IN NEUROEPIDEMIOLOGY
Sponsored by the American Academy of Neurology and endowed by GlaxoSmithKline, Inc.
Manya Prasad, MD
Institute of Liver and Biliary Sciences, New Delhi, India
CAREER DEVELOPMENT AWARD
Funded by the American Academy of Neurology.
Sasha Gupta, MD
University of California, San Francisco, San Francisco, CA
Krithi Irmady, MD, MBBS
Rockefeller University, New York, NY
CLINICAL RESEARCH TRAINING SCHOLARSHIP
Funded by the American Academy of Neurology.
Pritha Bisarad, PhD
University of Arizona, Phoenix, AZ
Kaitlin F. Farrell, MD, PhD
University of California, San Diego, San Diego, CA
Amanda M. Nagy, MD
Massachusetts General Hospital, Boston, MA
CLINICAL RESEARCH TRAINING SCHOLARSHIP IN ALD
Funded by Arrivederci ALD and American Brain Foundation in collaboration with the American Academy of Neurology.
Danielle (HyunJung) Kim, PhD
Stanford University, Palo Alto, CA
CLINICAL RESEARCH TRAINING SCHOLARSHIP IN ALS
Funded by the ALS Association and American Brain Foundation in collaboration with the American Academy of Neurology.
Joe Viteri, PhD
University of Missouri Next GEN Health Institute, Columbia, MO
CLINICAL RESEARCH TRAINING
SCHOLARSHIP IN FTD
Funded by The Holloway Family Fund of The Association for Frontotemporal Degeneration and the American Brain Foundation in collaboration with the American Academy of Neurology.
Janani Parameswaran, PhD
Emory University, Atlanta, GA
CLINICAL RESEARCH
TRAINING SCHOLARSHIP IN NEUROMUSCULAR DISEASE
Funded by the Neuromuscular Study Group and the American Brain Foundation.
Sophie Rengarajan, MD, PhD
Stanford Neurology, Palo Alto, CA
CLINICAL RESEARCH
TRAINING SCHOLARSHIP IN PARKINSON’S DISEASE
Funded by the Parkinson’s Foundation and the American Brain Foundation in collaboration with the American Academy of Neurology.
Laura de Lima Xavier, MD
Washington University, St. Louis, MO
CLINICAL RESEARCH TRAINING SCHOLARSHIP IN PERIPHERAL NEUROPATHY
Funded by the Foundation for Peripheral Neuropathy through the American Brain Foundation in collaboration with the American Academy of Neurology.
Tiffany Li, PhD
University of Sydney, Sydney, Australia
DREIFUSS-PENRY EPILEPSY AWARD
Sponsored by the American Academy of Neurology and endowed by members of the American Academy of Neurology Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Corporation; GlaxoSmithKline, Inc.; Novartis; OrthoMcNeil Pharmaceutical, Inc.; Pfizer Inc; Shire Pharmaceuticals Group; and UCB Pharma.
Alice D. Lam, MD, PhD
Massachusetts General Hospital, Boston, MA
H. RICHARD TYLER AWARD
Sponsored by the American Academy of Neurology and the American Academy of Neurology History Section.
Jonathan Williams, MD
Washington University, St. Louis, MO
HAROLD
WOLFF-JOHN GRAHAM AWARD: AN AWARD FOR HEADACHE/FACIAL PAIN RESEARCH
Sponsored by the American Academy of Neurology and endowed by Endo Pharmaceuticals.
Carlyn Patterson Gentile, MD
Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA
HEALTH CARE EQUITY PROGRAM
Omar M. Al-Janabi, MD, PhD, MSc
Baptist Health, Lexington, KY
Miya Asato, MD, FAAN
Kennedy Krieger Institute, Baltimore, MD
Fazila Aseem, MD, MPH
University of North Carolina Hospitals, Chapel Hill, NC
Sana Aslam, DO
University of Colorado, Aurora, CO
Nan Cheng, MD
University of California Irvine, Irvine, CA
Shannon M. DiCarlo, MD, FAAN
Baylor College of Medicine, Houston, TX
Qihua Fan, MD
Virginia Commonwealth University, Richmond, VA
Alexander Jonokuchi, MD
New York University Langone Medical Center, New York, NY
Laveena Singla, MD
University of Mississippi Medical Center, Jackson, MS
Muhammad I. Yousaf, MD
Virginia Tech Carilion School of Medicine, Roanoke, VA
HEALTH CARE EQUITY RESEARCH AWARD
Sponsored by the American Academy of Neurology.
Rachel Forman, MD
Yale University, New Haven, CT
Adys Mendizabal, MD, MS
University of California, Los Angeles, Los Angeles, CA
Lesli E. Skolarus, MD, MS
Northwestern University, Chicago, IL
JOHN DYSTEL PRIZE FOR MULTIPLE SCLEROSIS RESEARCH
Sponsored by the American Academy of Neurology and the National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society.
Amit Bar-Or, MD, FRCPC University of Pennsylvania, Philadelphia, PA
JON STOLK AWARD IN MOVEMENT DISORDERS FOR EARLY CAREER INVESTIGATORS
Sponsored by the American Academy of Neurology and endowed by Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, Dr. Dennis Gillings, and VelaPharma.
Shannon Y. Chiu, MD, MSc Mayo Clinic Arizona, Scottsdale, AZ
LAWRENCE C. MCHENRY: AN AWARD FOR THE HISTORY OF NEUROLOGY
Sponsored by the American Academy of Neurology.
Alison L. Christy, MD, PhD, FAAN Providence Health & Services, Portland, OR
Lawrence A. Zeidman, MD, FAAN Henry Ford Health, Detroit, MI
LAWRENCE M. BRASS STROKE RESEARCH AWARD
Funded by the American Heart Association and the American Brain Foundation in collaboration with the American Academy of Neurology.
Sigfus Kristinsson, PhD University of South Carolina, Columbia, SC
MCKNIGHT CLINICAL TRANSLATIONAL RESEARCH SCHOLARSHIP IN COGNITIVE AGING AND AGE-RELATED MEMORY LOSS
Funded by the McKnight Brain Research Foundation through the American Brain Foundation, and the American Academy of Neurology.
Giovanna Pilonieta, PhD, DMD, MPH University of Alabama, Birmingham, AL
Deborah Rose, MD National Institutes of Health, Bethesda, MD
MEDICAL STUDENT ESSAY
AWARD: G. MILTON SHY
Sponsored by the American Academy of Neurology.
Xaida Wright, BS University of California, Riverside School of Medicine, Riverside, CA
MEDICAL STUDENT ESSAY
AWARD: LEWIS P. ROWLAND
Sponsored by the American Academy of Neurology.
Daria Hoang, BA
Saint Louis University School of Medicine, St. Louis, MO
MEDICAL STUDENT ESSAY
AWARD: ROLAND P. MACKAY
Sponsored by the American Academy of Neurology.
Courtney N. Nguyen University of Texas Health Science Center McGovern Medical School, Houston, TX
MEDICAL STUDENT ESSAY
AWARD: SAUL R. KOREY
Sponsored by the American Academy of Neurology.
Kiran K. Sankarappan, BS
Texas A&M University College of Medicine, College Station, TX
MICHAEL S. PESSIN STROKE LEADERSHIP PRIZE
Sponsored by the American Academy of Neurology and endowed by Dr. Pessin’s family, friends, and colleagues.
Aristeidis Katsanos, MD, PhD McMaster University, Hamilton, ON, Canada
MITCHELL B. MAX
NEUROPATHIC PAIN AWARD
Sponsored by the American Academy of Neurology and endowed by the United States Cancer Pain Relief Committee, the Mayday Fund, and friends of Dr. Mitchell Max.
Brian Callaghan, MD, MS, FAAN University of Michigan Health System, Ann Arbor, MI
MOVEMENT DISORDERS RESEARCH AWARD
Sponsored by the American Academy of Neurology, the Parkinson’s Foundation, and the American Academy of Neurology Movement Disorders Section and endowed by the Parkinson’s Foundation.
Janis M. Miyasaki, MD, MEd, FAAN University of Alberta/Alberta Health Services, Edmonton, AB, Canada
NEURO-ONCOLOGY INVESTIGATOR AWARD
Sponsored by the American Academy of Neurology and supported by friends of Dr. Jerome Posner.
Mary Jane Lim-Fat, MD, FRCPC Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
NEURO-ONCOLOGY SCIENTIFIC AWARD
Sponsored by the American Academy of Neurology and supported by friends of Dr. WK Alfred Yung.
Adrienne Boire, MD, PhD, FAAN
Memorial Sloan-Kettering Cancer Center, New York, NY
NEUROSCIENCE RESEARCH PRIZE
Sponsored by the American Academy of Neurology.
Sofia Magalhaes
Ossining High School, Ossining, NY
Ashley Malkin
Greenwich High School, Greenwich, CT
Sharmada Palakurthi
W.B. Ray High School, Corpus Christi, TX
NEUROSCIENCE RESEARCH TRAINING SCHOLARSHIP
Funded by the American Academy of Neurology.
Carson Moseley, MD, PhD
University of California, San Francisco, San Francisco, CA
Mohit Rastogi, PhD
Stanford University, Stanford, CA NORMAN GESCHWIND PRIZE IN BEHAVIORAL NEUROLOGY.
Sponsored by the American Academy of Neurology and endowed through Dr. Geschwind’s family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral and Cognitive Neurology.
Matthew J. Burke, MD, FRCPC
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
The AAN would like to thank its research partner, the American Brain Foundation, for years of collaboration.
Learn about the NEW addition to our Parkinson’s portfolio.
See what’s going ON at booth 533
PRACTICE
RESEARCH TRAINING SCHOLARSHIP
Funded by the American Academy of Neurology. Jennifer Corcoran, MD University of Rochester, Rochester, NY
POTAMKIN PRIZE FOR RESEARCH IN PICK’S, ALZHEIMER’S, AND RELATED DISEASES
Sponsored by the American Academy of Neurology and the American Brain Foundation and funded through the philanthropy of the Potamkin family.
Gil D. Rabinovici, MD, FAAN
University of California, San Francisco Memory & Aging Center, San Francisco, CA
William W. Seeley, MD University of California, San Francisco, San Francisco, CA
RICHARD
OLNEY CLINICIAN SCIENTIST DEVELOPMENT AWARD IN ALS
Funded by the ALS Association and the American Brain Foundation in collaboration with the American Academy of Neurology.
Arens Taga, MD
Johns Hopkins University, Baltimore, MD
SHEILA ESSEY AWARD: AN AWARD FOR ALS RESEARCH
Presented by the American Brain Foundation, the American Academy of Neurology, the ALS Network, and the ALS Association, and supported through the philanthropy of the Essey family.
Christopher J. McDermott, MBChB, FRCP, PhD
University of Sheffield, Sheffield, South Yorkshire, United Kingdom
Neil A. Shneider, MD, PhD
Columbia University, New York, NY SLEEP SCIENCE AWARD
Sponsored by the American Academy of Neurology and the Sleep Section and endowed by Cephalon, Inc.
Mark I. Boulos, MD, FRCPC, CSCN(EEG), MSc
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
SUSAN S. SPENCER, MD, CLINICAL RESEARCH TRAINING SCHOLARSHIP IN EPILEPSY
Funded by the American Epilepsy Society, the Epilepsy Foundation, and the American Brain Foundation in collaboration with the American Academy of Neurology.
Peter N. Hadar, MD
Massachusetts General Hospital, Boston, MA
S. WEIR MITCHELL RESIDENT-FELLOW RESEARCH AWARD
Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.
Erik Lindgren, MD, PhD
Massachusetts General Hospital, Harvard Medical School, and University of Gothenburg, Boston, MA
Evangelos Pavlos Myserlis, MD
Medical University of South Carolina, Charleston, SC
WAYNE A. HENING SLEEP MEDICINE INVESTIGATOR AWARD
Sponsored by the American Academy of Neurology and endowed by UCB, Inc., Lilly USA, Elite Home Medical & Respiratory, Inc., Raleigh Neurology Associates, and friends of Dr. Wayne A. Hening.
Stephen Joza, MD, PhD
University of Alberta, Edmonton, AB, Canada
Have neurology career questions? Tonight’s reception has the answers!
Are you a medical student, resident, or fellow looking to give a boost to your neurology journey? Then tonight’s Trainee and Faculty Networking Reception is for you! Head on over to Marriott Marquis Pacific Ballroom between 6:00 p.m. to 8:00 p.m. to gain new perspectives and make lasting connections that could help further your career development in academic neurology, research, or practice. Faculty and representatives from nearly 100 institutions will be waiting to share their own professional experiences and discuss the prospects of residency, clerkships, fellowships, and other career opportunities. Connect with other trainees for insights and inspiration, and prepare to get all your questions answered about how you might traverse this exciting field!
Industry Therapeutic Update from Sanofi Medical Livestreaming is available on the 2025 AAN Annual Meeting Online Platform
An Evolving Paradigm: Challenging the Approach to Disability in MS
Tuesday April 8th, 11:45 AM PDT Room 6B, San Diego Convention Center
Doors open at 11:15 AM PDT Lunch will be served
You’ll hear from:
Join us at the 2025 AAN Annual Meeting for an exciting discussion and the opportunity to ask your questions in a live Q&A at the end of the session.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an o cial part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot a rm claims pertaining to FDA o -label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
